Patents for A61P 35 - Antineoplastic agents (221,099)
09/2011
09/15/2011WO2011110190A1 A cellobiose compound from herbal extracts having apoptotic activity
09/15/2011WO2011110087A1 Combined use of ribonuclease and artemisinsin
09/15/2011WO2011109899A1 Use of tigecycline for treatment of cancer
09/15/2011WO2011068403A3 Novel n-{3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamjne salts
09/15/2011WO2011066316A9 Treating neoplasms with neurotoxin
09/15/2011WO2011060332A3 Compositions and methods for treating hyperproliferative disorders
09/15/2011WO2011059836A3 T cell receptor-deficient t cell compositions
09/15/2011WO2011054837A3 Bifunctional prodrugs and drugs
09/15/2011WO2011044545A3 Methods and compositions for targeted imaging
09/15/2011WO2011031554A3 Heterocyclic compounds as janus kinase inhibitors
09/15/2011WO2011029028A3 Targeted delivery using tissue-specific peptidomimetic ligands
09/15/2011WO2011009714A3 Benzoquinolizinium salt derivatives as anticancer agents
09/15/2011WO2010104749A8 Antigen presenting cell targeted cancer vaccines
09/15/2011US20110224723 Cyanoacrylate tissue adhesives
09/15/2011US20110224608 Compound for Local Deletion of Tumors
09/15/2011US20110224415 Human muty
09/15/2011US20110224313 Compositions and methods for classifying lung cancer and prognosing lung cancer survival
09/15/2011US20110224302 Difluorophenyldiacylhydrazide derivatives
09/15/2011US20110224294 Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
09/15/2011US20110224290 Combine use of pterostilbene and quercetin for the production of cancer treatment medicaments
09/15/2011US20110224289 Compounds of the pterocarpanquinone family, method for preparing the same, pharmaceutical composition containing the new compounds of the pterocarpanquinone family, uses and therapeutic method
09/15/2011US20110224288 Cancer Cell Targeting Using Nanoparticles
09/15/2011US20110224286 MICRO RNA (MiRNA) AND NEUROFIBROMATOSIS TYPE 1: A ROLE IN DIAGNOSIS AND THERAPY
09/15/2011US20110224285 Oligomeric compounds for the modulation of hif-1a expression
09/15/2011US20110224284 Putative tumor suppressor microrna-101 modulates the cancer epigenome by repressing the polycomb group protein ezh2
09/15/2011US20110224281 Rna antagonists targeting hsp70-2
09/15/2011US20110224279 Anticancer agent
09/15/2011US20110224275 Inhibitors of matrix metalloproteinases
09/15/2011US20110224274 New Therapeutic Agents
09/15/2011US20110224267 Selective androgen receptor modulators
09/15/2011US20110224259 Novel inhibitors
09/15/2011US20110224254 Novel inhibitors
09/15/2011US20110224253 Small-molecule inhibitors of the androgen receptor
09/15/2011US20110224251 Therapeutic Pyrazolyl Thienopyridines
09/15/2011US20110224248 Azaquinolones that inhibit prolyl hydroxylase
09/15/2011US20110224246 Pharmaceutical compositions comprising ascomycin
09/15/2011US20110224240 Methods of treating cancer and related diseases
09/15/2011US20110224235 Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
09/15/2011US20110224229 Novel Crystalline Form
09/15/2011US20110224225 Inhibitors of protein kinases
09/15/2011US20110224224 Method of Optimizing the Treatment of Philadelphia-Positive Leukemia with Imatinib Mesylate
09/15/2011US20110224223 MTOR Modulators and Uses Thereof
09/15/2011US20110224222 Cdk inhibitor for the treatment of mesothelioma
09/15/2011US20110224220 Substituted tricyclic derivatives
09/15/2011US20110224218 Method for inhibiting growth of cancer cells and cell telomere and diseases of cell proliferation by using heteroannelated anthraquinone derivative compounds
09/15/2011US20110224217 Methods of treatment using heteroaryl compounds and compositions thereof
09/15/2011US20110224212 Kinase inhibitor compounds
09/15/2011US20110224206 Triazole compounds that modulate hsp90 activity
09/15/2011US20110224205 Use of curcumin or its analogues in cancer therapy utilizing epidermal growth factor receptor tyrosine kinase inhibitor
09/15/2011US20110224203 Benzimidazole derivatives and their use as protein kinase inhibitors
09/15/2011US20110224194 Staurosporine Derivatives as Inhibitors of FLT3 Receptor Tyrosine Kinase Activity
09/15/2011US20110224192 3-Arylamino Pyridine Derivatives
09/15/2011US20110224191 Substituted Pyrrolo[2,3-b]-Pyridines and -Pyrazines
09/15/2011US20110224190 Piperidin-4-yl azetidine derivatives as jak1 inhibitors
09/15/2011US20110224189 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
09/15/2011US20110224183 16, 17-carbocyclic condensed steroid compounds having slective estrogenic activity
09/15/2011US20110224175 Formulations of canfosfamide and their preparation
09/15/2011US20110224162 Synthetic analogues of phosphatidyl-myo-inositol mannosides with an inhibitory activity of the inflammatory response
09/15/2011US20110224161 Tetracyclic anthraquinone antibiotic derivatives with high activity, process for preparing the same and use thereof
09/15/2011US20110224159 Bidesmosidic betulin and betulinic acid derivatives and uses thereof as antitumor agents
09/15/2011US20110224158 Esterified alpha-galactosylceramide
09/15/2011US20110224157 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
09/15/2011US20110224151 Polymeric Micelle Composition for Treatment of Resistant Cancer and Preparation Method of the Same
09/15/2011US20110224150 Methods for effecting regression of tumor mass and size in a metastasized tumor
09/15/2011US20110224149 Polynucleotides for use in treating and diagnosing cancers
09/15/2011US20110224148 Carbohydrate-polyamino acid-drug conjugates
09/15/2011US20110224142 Parathyroid hormone receptor activation and stem and progenitor cell expansion
09/15/2011US20110224141 Methods and related compositions for the treatment of cancer
09/15/2011US20110224133 Highly Potent Peptides To Control Cancer And Neurodegenerative Diseases
09/15/2011US20110223658 Monoclonal antibodies with enhanced adcc function
09/15/2011US20110223271 Phytocomplex from bergamot fruit, process of manufacture and use as dietary supplement and in the pharmaceutical field
09/15/2011US20110223255 Implantable products comprising nanoparticles
09/15/2011US20110223249 Extended release compositions comprising mycophenolate sodium and processes thereof
09/15/2011US20110223241 Combination methods and compositions
09/15/2011US20110223233 Microfabricated nanopore device for sustained release of therapeutic agent
09/15/2011US20110223221 Stabilization processes of cation radicals of phenothiazinic compounds, cosmeceutical formulations and methods for skin diseases and disturbances prevention
09/15/2011US20110223216 Nanoparticles and Porous Particles and Methods of Making the Same
09/15/2011US20110223214 Use of carboxymethylcellulose to control ejectability and solidification time of compositions comprising one or more bioresorbable ceramics
09/15/2011US20110223210 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
09/15/2011US20110223208 Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
09/15/2011US20110223203 Nanocluster compositions and methods
09/15/2011US20110223191 Anti-cancer nutraceutical composition
09/15/2011US20110223188 Targeted costimulatory polypeptides and methods of use to treat cancer
09/15/2011US20110223187 Live listeria-based vaccines for central nervous system therapy
09/15/2011US20110223183 Human notch3 based fusion proteins as decoy inhibitors of notch3 signaling
09/15/2011US20110223182 Monoclonal antibodies for treatment of cancer
09/15/2011US20110223181 Gene expression profiling in primary ovarian serous papillary tumors and normal ovarian epithelium
09/15/2011US20110223180 Methods and compositions related to a multi-methylation assay to predict patient outcome
09/15/2011US20110223176 Basigin binding proteins
09/15/2011US20110223171 Methods and Compositions for the Diagnosis and Treatment of Cyclin A-1 Associated Conditions
09/15/2011US20110223167 Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
09/15/2011US20110223165 Humanized C-Kit Antibody
09/15/2011US20110223164 Binding domain-immunoglobulin fusion proteins
09/15/2011US20110223162 Targeting pax2 for the treatment of breast cancer
09/15/2011US20110223161 Targeting pax2 for the treatment of breast cancer
09/15/2011US20110223159 Tumor therapy with an anti-vegf antibody
09/15/2011US20110223155 Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
09/15/2011US20110223154 Compositions including triciribine and methods of use thereof
09/15/2011US20110223153 Modified silk films containing glycerol
09/15/2011US20110223152 Use of inhibitors of leukotriene b4 receptor blt2 for treating human cancers